Anixa Biosciences, Inc. booked $210.0k in FY2024 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -5203.3% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.